Literature DB >> 20716481

Palliative radiotherapy for non-melanoma skin cancer.

E A Barnes1, D Breen, S Culleton, L Zhang, J Kamra, M Tsao, J Balogh.   

Abstract

AIMS: The primary objective of this study was to assess the rate of tumour response to the palliative radiotherapy regimen used at our centre (8 Gy/fraction on days 0, 7, 21) for non-melanoma skin cancer. The secondary objective was to evaluate symptom palliation.
MATERIALS AND METHODS: A retrospective chart review identified patients treated with this palliative radiotherapy regimen from August 2003 to December 2008. Patient age, gender, tumour histology, location, size, presenting symptoms and radiation treatment factors were recorded at baseline. The tumour size and tumour-related symptoms were recorded at each fraction and follow-up visit. The results were analysed on an intent to treat basis.
RESULTS: Twenty-eight patients received 31 courses of palliative radiation for basal cell (five) or squamous cell (26) carcinoma of the skin. Twenty-one patients with 23 tumours attended at least one follow-up visit, and seven patients had incomplete follow-up data. At the time of last follow-up (median 17 weeks), the response rate was 58.1% (complete response 15/31; partial response 3/31). A complete response to treatment was correlated with a smaller tumour size at day 21 (P=0.0143). Presenting symptoms were alleviated in 61.3% (19/31) of symptomatic sites. No severe late toxicities were seen.
CONCLUSIONS: This palliative regimen offers impressive response rates and effective symptom palliation for patients with non-melanoma skin cancer.
Copyright © 2010 The Royal College of Radiologists. Published by Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20716481     DOI: 10.1016/j.clon.2010.07.014

Source DB:  PubMed          Journal:  Clin Oncol (R Coll Radiol)        ISSN: 0936-6555            Impact factor:   4.126


  9 in total

1.  Radiotherapy treatment of non-melanoma skin cancer: a survey of current UK practice and commentary.

Authors:  A J McPartlin; N J Slevin; A J Sykes; A Rembielak
Journal:  Br J Radiol       Date:  2014-09-05       Impact factor: 3.039

2.  Role of stereotactic body radiotherapy for symptom control in head and neck cancer patients.

Authors:  Luluel Khan; Michael Tjong; Hamid Raziee; Justin Lee; Darby Erler; Lee Chin; Ian Poon
Journal:  Support Care Cancer       Date:  2014-10-09       Impact factor: 3.603

Review 3.  Symptoms of and Palliative Treatment for Unresectable Skin Cancer.

Authors:  Hiroyuki Goto; Yoshio Kiyohara; Masahisa Shindo; Osamu Yamamoto
Journal:  Curr Treat Options Oncol       Date:  2019-03-27

Review 4.  The State of the Art of Radiotherapy for Non-melanoma Skin Cancer: A Review of the Literature.

Authors:  Sofian Benkhaled; Dirk Van Gestel; Carolina Gomes da Silveira Cauduro; Samuel Palumbo; Veronique Del Marmol; Antoine Desmet
Journal:  Front Med (Lausanne)       Date:  2022-06-27

5.  SBRT Treatment of Multiple Recurrent Auricular Squamous Cell Carcinomas Following Surgical and Conventional Radiation Treatment Failure.

Authors:  Drew Brotherston; Ian Poon
Journal:  Cureus       Date:  2015-09-17

Review 6.  Palliative radiotherapy.

Authors:  Katie Spencer; Rhona Parrish; Rachael Barton; Ann Henry
Journal:  BMJ       Date:  2018-03-23

7.  Radiotherapy can cause haemostasis in bleeding skin malignancies.

Authors:  Helena Sung-In Jang; Andrew Spillane; Frances Boyle; Gerald Fogarty
Journal:  Case Rep Med       Date:  2012-12-30

8.  Giant ulcerative lesion on the upper back: using a differential diagnosis to formulate a clinical approach.

Authors:  Ryan David Wagner; Harrison Phu Nguyen; Stephen Keith Tyring
Journal:  Einstein (Sao Paulo)       Date:  2016 Jan-Mar

9.  Bleeding in Locally Invasive Pelvic Malignancies: Is Hypofractionated Radiation Therapy a Safe and Effective Non-Invasive Option for Securing Hemostasis? A Single Institution Perspective.

Authors:  Muhammad Shuja; Saadiya Nazli; Muhammad Atif Mansha; Asif Iqbal; Reham Mohamed; Mutahir A Tunio; Eyad F Alsaeed; Mushabbab Asiri; Yasser Bayoumi
Journal:  Cureus       Date:  2018-02-02
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.